13. IAS Konferenz in Kigali

Die Konferenz fand nicht nur in Afrika statt, sie stand auch ganz im Zeichen von HIV in Afrika. Viele Arbeiten beschäftigten sich mit den Auswirkungen der finanziellen Kürzungen, der Zukunft der Prävention und den Effekten der ART im afrikanischen Setting. Darüber hinaus wurden aber auch neue Medikamente, Kohorten-Auswertungen und neue Leitlinien vorgestellt. Ein Bericht über den Kongress erscheint in Infection&more 3/2025

PDF/PPT zum Download

ViiV Healthcare

CABOTEGRAVIR + RILPIVIRINE Long-acting for treatment
Perspectives of healthcare providers on long-acting injectable cabotegravir and rilpivirine delivery in clinic and community settings in the UK: longitudinal survey findings from the ILANA study* Chloe Orkin et al. - E-Poster	View Abstract
The power of choice: strong preference for CAB+RPV LA following rapid suppression with DTG/3TC in newly diagnosed people living with HIV Franco Felizarta et al. - E-Poster	View Poster
Real-world Effectiveness of CAB+RPV LA in Individuals with HIV Viremia at Therapy Initiation Ricky K. Hsu et al. - Oral Presentation	View Poster
Clinical Outcomes Among Women in the OPERA Cohort Initiating CAB+RPV LA with Viral Loads ≥ 50 copies/mL Jessica Altamarino et al. - In-person Poster	View Poster
High virologic suppression and few virologic failures with Long-Acting Cabotegravir + Rilpivirine in Treatment Experienced Virologically Suppressed Individuals from COMBINE-2 cohort in Europe Anton Pozniak et al. - E-Poster	View Poster
Perspectives of people with HIV (PWH) 24 months following a switch to cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world US study (BEYOND) Franco Felizarta et al. - In-person Poster	View Poster
Clinical Outcomes at Month 24 After Initiation of Cabotegravir and Rilpivirine Long Acting (CAB+RPV LA) in an Observational Real-World Study (BEYOND) Gary Blick et al. - E-Poster	View Poster
24-month outcomes of cabotegravir+rilpivirine long-acting every 2 months in a real-world setting: effectiveness, adherence to injections, and participant-reported outcomes from people with HIV-1 in the German CARLOS cohort Christoph Wyen et al. - In-person Poster	View Poster
Pregnancy and Neonatal Outcomes Following Prenatal Exposure to Cabotegravir (CAB): Data from The Antiretroviral Pregnancy Registry (APR) Vani Vannappagari et al. - Oral Presentation	View Poster
DOLUTEGRAVIR-based regimens
Virological outcomes of adolescents switched to dolutegravir based regimens at Botswana-Baylor Children's Clinical Centre of Excellence (BBCCCOE), 2016 to 2023* John Farirai et al. - E-Poster	View Abstract
Predictors of treatment failure in children living with HIV starting first-line antiretroviral therapy in the ODYSSEY trial* James Wyncoll et al. - Oral Presentation	View Abstract
Efficacy of dolutegravir plus lamivudine in treatment-naïve people with HIV with baseline transmitted drug-resistance mutations: a subanalysis of the D2ARLING study* E. Cordova et al. - E-Poster	View Abstract
Patient-Reported Outcomes among virally suppressed people living with HIV switching to dolutegravir/lamivudine vs. continuing bictegravir/emtricitabine/tenofovir alafenamide from the randomized DYAD study* Charlotte-Paige Rolle et al. - E-Poster	View Abstract
Impact of Dual Therapy on Weight Gain and Metabolic Outcomes in Naïve People living with HIV (PLHIV) with CD4 Counts <200 Cells/mm3: Findings from the DOLCE Study* M. Figueroa et al. - E-Poster	View Abstract
The Impact of Immune Reconstitution Inflammatory Syndrome (IRIS) in HIV-Positive People with CD4 <200 Cells/mm3 Initiating Dolutegravir/Lamivudine Dual Therapy: DOLCE Study Findings* C. Brites et al. - In-person Poster	View Abstract
Is exclusion of tenofovir from antiretroviral regimens safe in Africa: insights on hepatitis B from the switch to DTG/3TC (Sungura) study* Loice Achieng Ombajo et al. - In-person Poster	View Abstract
Efficacy and safety of switching to dolutegravir/lamivudine dual therapy from bictegravir/emtricitabine/tenofovir alafenamide among virally suppressed older adults ≥60 years: week 24 results from the Sungura study* Loice Achieng Ombajo et al. - In-person Poster	View Abstract
Rapid virologic suppression with DTG/3TC facilitates early switch to CAB+RPV LA for treatment-naive people living with HIV: Suppression Phase outcomes from the Phase 3b VOLITION study Ezequiel Córdova et al. - In-person Poster	View Poster

*denotes ViiV-supported investigator led and collaborative studies

Über den untenstehenden Link erhalten Sie Zugriff auf alle von ViiV gesponserten sowie von ViiV-unterstützten Kooperationsstudien, die beim IAS 2025 präsentiert wurden – darunter auch Studien zu Cabotegravir zur Prävention und weitere HIV-bezogene Publikationen.